Platform technologies

ReNeuron's stem cell products are derived from non-embryonic human tissue sources. Our stem cell therapy programmes have been built around our unique and highly efficient stem cell expansion technology, c-mycER. This platform enables, from a single tissue sample, the growth of selected human stem cells into banks of quality-assured stem cell lines. These stem cell lines contain enough stem cells to treat many thousands of potential patients. This capability has enabled us to focus on developing non-patient-specific, or allogeneic, stem cell treatments addressing diseases with large patient populations. The stem cell expansion process is fully regulated by way of a chemically induced safety switch so that cell growth can be arrested before implantation of the stem cells into the patient.

Using the c-mycER cell expansion technology, we are able to readily scale-up our stem cell lines for clinical and commercial use without the need to re-derive those cell lines from an earlier, non-quality assured prototype.This gives ReNeuron a significant competitive advantage in terms of the time and expense in moving a potential stem cell therapy through a clinical development programme.

We have also developed a unique screening platform using our c-mycER technology that enables the selection of optimal stem cell lines for further development as a treatment for the relevant disease.Selection criteria during cell screening include cell phenotype, ability to expand into large-scale culture, and capacity to engraft in the relevant disease model with minimal immune rejection by the host.

Our micmac® cell encapsulation technology provides a method of protecting cells when transplanted, as well as reducing or eliminating the host immune response that might otherwise occur post-transplantation in certain clinical settings.This cell encapsulation platform has already been shown to be effective clinically, when micmac® encapsulated, insulin-producing primary islet cells were implanted into patients suffering from Type 1 diabetes.We are currently testing the potential of this platform when combined with our own cell lines generated using the c-mycER platform, both pancreatic and neural.

Top of page